Cipla Limited: Comprehensive Stock Analysis Report | Scrolls

by KarNivesh | 13 August, 2025

Cipla Limited- Scrolls.pdf

Download PDF • 612KB

Overview

Cipla Limited, one of India’s leading pharmaceutical companies, stands out for its strong fundamentals, global presence, and diversified portfolio. As of August 13, 2025, it trades at ₹1,561 with a market capitalization of ₹1,26,098 crores. FY25 saw a 27.9% profit growth, reaching ₹5,273 crores, supported by an almost debt-free balance sheet.

Business Profile & Market Position: Founded in 1935, Cipla is India’s third-largest pharmaceutical firm by market share and South Africa’s top prescription medicine provider. Operating in 80+ countries through 46 manufacturing facilities, it offers over 1,500 products in 50 dosage forms. It leads the Indian respiratory market (24.6% share), ranks strong in urology (11.9%), and chronic care (8.6%). Its respiratory brand Foracort generates ₹83 crore in monthly sales.

Strategic Developments: In 2025, Cipla entered India’s weight management market to address rising obesity rates. It acquired a 20% stake in iCaltech Innovations for ₹5 crores, enhancing its respiratory diagnostics portfolio. The company secured USFDA approval for its generic version of Abraxane (₹9,960 crores globally) for multiple cancers, expected to launch in H1 FY26. Additionally, Cipla in-licensed Sanofi’s CNS range in India, targeting epilepsy, ADHD, and Parkinson’s segments.

Financial Performance: Revenue grew from ₹18,989 crores in FY21 to ₹27,145 crores in FY25 (9% CAGR). Net profit margins improved from 12.7% to 19.4%, driven by high-margin products and efficiency gains. EPS rose from ₹29.79 to ₹65.24 over four years. EBITDA margins stood at 26%, among the highest in the sector.

Cipla's revenue and profit growth trend over the past 5 years, showing strong financial performance with accelerating profit growth

Balance Sheet & Cash Flows: With total assets of ₹37,387 crores and equity of ₹31,193 crores, Cipla’s debt-to-equity ratio is just 0.014. Debt reduced from ₹2,014 crores in FY21 to ₹438 crores in FY25, backed by ₹800 crores in cash reserves. Operating cash flow reached ₹5,005 crores in FY25, with free cash flow at ₹3,843 crores.

Ownership & Governance: As of June 2025, promoters hold 29.19% (down from 33.47% in 2023). Institutional investors own 54.49% (FIIs 25.24%, mutual funds 20.44%, insurance firms 6.81%). Retail investors hold 16.31%. The board has a majority of independent directors, led by MD & Global CEO Umang Vohra.

Cipla's ownership structure showing balanced mix of promoter, institutional and retail shareholding

Valuation & Peers: Cipla’s P/E is 23.92 vs. the industry average of 33.67, and its P/B is 4.04. It ranks second in market cap among peers, behind Sun Pharma but ahead of Dr. Reddy’s, Torrent Pharma, and Lupin.

Growth Strategy: Cipla’s India business contributes ₹11,700 crores, North America ₹8,150 crores, South Africa ₹2,600 crores, with the rest from emerging markets and APIs. R&D spending of ₹1,571 crores (6% of revenue) focuses on complex generics, biosimilars, and novel drug delivery.

Risks & Outlook: Key risks include US market pricing pressures, regulatory challenges, currency fluctuations, and reliance on respiratory products. However, diversification into weight management, CNS, and diagnostics mitigates these risks.